The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, ...

The combination therapy can be used as first-line treatment for unresectable or metastatic forms of the cancer.

The combination of nivolumab with ipilimumab was approved for unresectable or metastatic microsatellite instability-high (MSI ...

Nivolumab plus ipilimumab showed a strong median overall survival (OS) advantage at 12 months and a trend toward overall ...

OS rates were not available at the time of the analysis. Patients receiving combination nivolumab and ipilimumab received 240 mg nivolumab every 3 weeks plus 1 mg/kg ipilimumab every 3 weeks for ...

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck ...

Participants received 1 of 3 regimens: Nivolumab 240 mg every 3 weeks plus ipilimumab 1 mg/kg every 3 weeks for 4 doses, followed by nivolumab 480 mg every 4 weeks Nivolumab 240 mg every 2 weeks for 6 ...

The FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). This regulatory decision is ...

The recommended nivolumab dose is 1 mg/kg with ipilimumab 3 mg/kg intravenously every three weeks for a maximum of four doses, followed by nivolumab 240 mg IV every 2 weeks or nivolumab 480 mg IV as a ...

In this trial, patients were randomized to receive either 240 mg of nivolumab every 3 weeks and 1 mg/kg of ipilimumab every 3 weeks for a maximum of 4 doses followed by 480 mg of nivolumab every 4 ...

Patients were randomized to receive one of the following treatments: nivolumab 240 mg every 3 weeks and ipilimumab 1 mg/kg every 3 weeks for a maximum of 4 doses, then nivolumab 480 mg every 4 weeks, ...